Neuphoria Therapeutics Inc.
NEUP Nasdaq
SEC CIK 1191070
Follow Neuphoria Therapeutics
Weekly email: filings, results
Revenue, last year
AUD 22K
−91.6% vs prior year
Net income
−AUD 31.8M
−3586.7% vs prior year
EPS, diluted
−AUD 0.02
+0% vs prior year
Operating cash flow
−AUD 21.3M
+1.9% vs prior year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY23 | AUD 22K | −AUD 31.8M |
| FY22 | AUD 263.6K | AUD 913.4K |
| FY21 | - | AUD 892.5K |
| FY20 | AUD 46.7K | - |
| FY19 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY23 | - |
| FY22 | −AUD 21.8M |
| FY21 | −AUD 7.5M |
| FY20 | −AUD 3.9M |
| FY19 | - |